About this trial
A method of ICG counterstaining localization under target artery occlusion without cutting,It's a new method of localization of small pulmonary nodules.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
<1cm CTR≤0.75; <1.5cm CTR≤0.5; <2cm CTR≤0.25 Lung nodules
The tumor center is located in the peripheral 2/3 area of the lung field
Preoperative analysis and planning of watershed by 3D reconstruction
Clinically assessed as cT1aN0M0 stage IA1/cT1bN0M0 stage IA2 (eighth edition), clinically resectable
Disqualifiers
No surgical video, no postoperative gross specimen and related distance measurement records
The incision edge does not exceed the target nodule diameter from the nodule edge
The resection range exceeds 50% of the preoperative planning
Postoperative pathological staging non-pT1aN0M0 IA1 stage/pT1bN0M0 IA2 stage (eighth edition)
Trial design
Single group
Treatments tested in this trial
Wedge resection under watershed analysis method
Procedure/Surgery* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery; * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule
Treatment groups
Trial outcomes
Primary outcomes
Lung fuction
testing FEV1 and FVC with MIR Spirolab
Sponsors and contacts
Click on the lead sponsor to view all of their trials.